Fulgent Genetics, Inc. (FLGT)
USD 17.92
(0.34%)
USD 17.92
(0.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -72.69 Million USD | -142.18% |
| 2022 | 178.52 Million USD | -73.59% |
| 2021 | 675.95 Million USD | 132.96% |
| 2020 | 290.15 Million USD | 67893.93% |
| 2019 | -428 Thousand USD | 91.54% |
| 2018 | -5.05 Million USD | -48.74% |
| 2017 | -3.4 Million USD | -469.97% |
| 2016 | 919 Thousand USD | 118.34% |
| 2015 | -5.01 Million USD | -406.26% |
| 2014 | -990 Thousand USD | 0.0% |
| 2001 | 104.33 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -21.79 Million USD | 29.43% |
| 2024 Q2 | -18.9 Million USD | 13.27% |
| 2023 Q1 | -24.82 Million USD | 32.13% |
| 2023 FY | -75.29 Million USD | -142.18% |
| 2023 Q4 | -30.88 Million USD | -14533.18% |
| 2023 Q3 | 214 Thousand USD | 101.08% |
| 2023 Q2 | -19.79 Million USD | 20.25% |
| 2022 Q3 | 562 Thousand USD | -96.98% |
| 2022 FY | 178.52 Million USD | -73.59% |
| 2022 Q1 | 201.93 Million USD | 33.85% |
| 2022 Q2 | 18.58 Million USD | -90.8% |
| 2022 Q4 | -36.57 Million USD | -6608.54% |
| 2021 Q4 | 150.86 Million USD | -5.28% |
| 2021 FY | 675.95 Million USD | 132.96% |
| 2021 Q1 | 266.92 Million USD | 18.15% |
| 2021 Q3 | 159.27 Million USD | 61.05% |
| 2021 Q2 | 98.89 Million USD | -62.95% |
| 2020 Q4 | 225.9 Million USD | 255.63% |
| 2020 Q1 | -1.91 Million USD | -367.97% |
| 2020 Q2 | 2.64 Million USD | 237.93% |
| 2020 Q3 | 63.52 Million USD | 2306.17% |
| 2020 FY | 290.15 Million USD | 67893.93% |
| 2019 Q2 | 295 Thousand USD | 116.18% |
| 2019 Q3 | 1.5 Million USD | 411.53% |
| 2019 Q4 | -409 Thousand USD | -127.1% |
| 2019 FY | -428 Thousand USD | 91.54% |
| 2019 Q1 | -1.82 Million USD | -79.43% |
| 2018 Q3 | -846 Thousand USD | 15.48% |
| 2018 Q1 | -2.19 Million USD | -10.36% |
| 2018 FY | -5.05 Million USD | -48.74% |
| 2018 Q4 | -1.01 Million USD | -20.09% |
| 2018 Q2 | -1 Million USD | 54.38% |
| 2017 Q1 | 219 Thousand USD | -82.61% |
| 2017 FY | -3.4 Million USD | -469.97% |
| 2017 Q4 | -1.98 Million USD | -34.23% |
| 2017 Q3 | -1.48 Million USD | -887.33% |
| 2017 Q2 | -150 Thousand USD | -168.49% |
| 2016 Q3 | -611 Thousand USD | -162.99% |
| 2016 Q1 | -615 Thousand USD | 91.63% |
| 2016 Q2 | 970 Thousand USD | 257.72% |
| 2016 Q4 | 1.25 Million USD | 306.06% |
| 2016 FY | 919 Thousand USD | 118.34% |
| 2015 Q1 | 405 Thousand USD | 0.0% |
| 2015 Q2 | 746 Thousand USD | 84.2% |
| 2015 Q4 | -7.34 Million USD | -722.37% |
| 2015 Q3 | 1.18 Million USD | 58.18% |
| 2015 FY | -5.01 Million USD | -406.26% |
| 2014 FY | -990 Thousand USD | 0.0% |
| 2001 FY | 104.33 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 25.332% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -563.682% |
| Aspira Women's Health Inc. | -18.85 Million USD | -285.609% |
| Biodesix, Inc. | -41.34 Million USD | -75.838% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -2702.874% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -811.739% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -811.739% |
| Bionano Genomics, Inc. | -215.24 Million USD | 66.227% |
| CareDx, Inc | -101.9 Million USD | 28.66% |
| Check-Cap Ltd. | -19.28 Million USD | -276.912% |
| Castle Biosciences, Inc. | -67.97 Million USD | -6.941% |
| DarioHealth Corp. | -56.18 Million USD | -29.376% |
| Exact Sciences Corporation | -215.01 Million USD | 66.19% |
| Guardant Health, Inc. | -564.72 Million USD | 87.127% |
| ICON Public Limited Company | 956.15 Million USD | 107.603% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 106.626% |
| Illumina, Inc. | -1.06 Billion USD | 93.2% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -606.932% |
| iSpecimen Inc. | -11.16 Million USD | -550.844% |
| Standard BioTools Inc. | -76.6 Million USD | 5.098% |
| MDxHealth SA | -27.32 Million USD | -166.019% |
| 23andMe Holding Co. | -321.35 Million USD | 77.379% |
| Medpace Holdings, Inc. | 336.82 Million USD | 121.582% |
| Myriad Genetics, Inc. | -123.7 Million USD | 41.233% |
| Mainz Biomed B.V. | -26.64 Million USD | -172.831% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -590.969% |
| NeoGenomics, Inc. | -107.73 Million USD | 32.525% |
| Neogen Corporation | 58.66 Million USD | 223.92% |
| Inotiv, Inc. | -81.46 Million USD | 10.76% |
| Natera, Inc. | -446.24 Million USD | 83.71% |
| OpGen, Inc. | -15.68 Million USD | -363.366% |
| OPKO Health, Inc. | -157.02 Million USD | 53.704% |
| Psychemedics Corporation | -2.92 Million USD | -2388.702% |
| Prenetics Global Limited | -52.51 Million USD | -38.431% |
| Prenetics Global Limited | -52.51 Million USD | -38.431% |
| Precipio, Inc. | -7.62 Million USD | -854.003% |
| Personalis, Inc. | -109.93 Million USD | 33.875% |
| RadNet, Inc. | 98.69 Million USD | 173.655% |
| Sera Prognostics, Inc. | -39.82 Million USD | -82.554% |
| Sotera Health Company | 276.69 Million USD | 126.273% |
| Neuronetics, Inc. | -30.55 Million USD | -137.923% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1572.688% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1572.688% |
| Trinity Biotech plc | -27.04 Million USD | -168.793% |
| T2 Biosystems, Inc. | -49.66 Million USD | -46.374% |
| Twist Bioscience Corporation | -220.83 Million USD | 67.081% |
| Exagen Inc. | -22.83 Million USD | -218.321% |